ASH 2023 | Clinical and prognostic implications of WT1 mutations in de novo and R/R AML
Sanam Loghavi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, speaks on a study examining the prognostic impact of WT1 mutations, often co-occurring with NPM1 and FLT3-ITD mutations, in acute myeloid leukemia (AML). Although WT1 mutations did not independently affect overall survival (OS) in this study, they were highly enriched in relapsed/refractory (R/R) cases compared to de novo disease, suggesting their acquisition throughout the disease course. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consultancy: QualWorld, Gerson Lehrman Group, Abbvie, Blueprint Medicine, Caris Diagnostics, Guidepoint, Recordati/ EUSA Pharma, Daiichi Sankyo
Research Funding: Astellas, Amgen
Current equity holder in publicly-traded company: Abbvie
